Nicholas C. Rohs, MD

Articles

Closing Out With KRAS and HER2 Advances in NSCLC

January 7th 2022

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD; conclude this series by discussing encouraging data and updates in non–small cell lung cancer treatment for patients who harbor KRAS and HER2 abnormalities.

Revolutionizing Targeted Therapy With EGFR Exon 20 and the Early-Stage NSCLC Setting

January 7th 2022

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD, discuss the updates with targeted therapy as it relates to the early-stage setting of non–small cell lung cancer as well as those who harbor EGFR exon 20 insertion mutations.

How Has Immunotherapy Evolved in the Advanced NSCLC Setting?

January 7th 2022

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD, highlight new therapeutic advances in the advanced setting of non–small cell lung cancer unveiled throughout 2021.

Shaping the Use of Immunotherapy in the Localized Lung Cancer Setting

January 7th 2022

Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year. This episode is a review of the clinical advancements in lung cancer treatment throughout 2021. Funding from Daiichi Sankyo/Content Independently Developed by OncLive

Reviewing the Year 2021 in Lung Cancer Treatment

December 22nd 2021

Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.

Liquid Biopsies and Molecular Testing in NSCLC

April 9th 2021

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss the significance of molecular testing in clinical practice and the evolution of liquid biopsies in lung cancer treatment.

Meeting MET-Amplified NSCLC With Progress

April 9th 2021

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss promising agents in the treatment of patients with non–small cell lung cancer with MET amplification.

What's Happening in KRAS G12C+ NSCLC?

April 9th 2021

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss the latest findings in KRAS G12C–positive non–small cell lung cancer.

Updates in EGFR+ NSCLC, Including Uncommon EGFR Mutations

April 9th 2021

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss data from the IASLC 2020 World Conference on Lung Cancer focused on EGFR-positive non–small cell lung cancer.

HER2-Directed Advances in Lung Cancer

April 9th 2021

Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.

Dr. Rohs on the Role of Molecular Testing in Lung Cancer Management

January 18th 2021

Nicholas C. Rohs, MD, discusses the role of molecular testing in patients with lung cancer.

Dr. Rohs on the Importance of Genetic Testing in NSCLC

November 7th 2020

Nicholas C. Rohs, MD, discusses the importance of genetic testing in non–small cell lung cancer.

Dr. Rohs on the Use Liquid Biopsies in Lung Cancer

January 14th 2020

Nicholas C. Rohs, MD, assistant professor of medicine, hematology, and medical oncology, Icahn School of Medicine, Mount Sinai, discusses the use of liquid biopsies in lung cancer.